[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arterial-thromboembolism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arterial-thromboembolism":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,72,102,124,160],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100619890","aspiration-thrombectomy-using-the-symphony-or-prodigy-system-100619890",false,"NCT07350499","Aspiration Thrombectomy Using the Symphony or Prodigy System","Long-Term CLinical Evaluation of Aspiration ThRombectomy Using the Symphony or ProdIgy Thrombectomy System - CLEAR-IT","CLEAR-IT","Inclusion Criteria:\n\n1. Subject is ≥ 18 years of age\n2. Subject is willing and able to comply with the follow-up schedule specified in this protocol\n3. Subject is willing and able to provide written informed consent prior to any study-related data collection\n4. Subject has a planned procedure, involving the use of Imperative Care vascular devices within their intended use\n\nExclusion Criteria:\n\n1. Subjects with any contraindications per the applicable Instructions for Use\n2. Subject with life expectancy of less than 1 year\n3. In the opinion of the Investigator, the patient is not a suitable candidate for intervention with Imperative Care devices\n4. Subject who may be unable to complete study follow-up\n5. Peripheral Venous Cohort ONLY: Presence of thrombus extending more than 2 cm into the IVC on imaging","ALL","18 Years",{"count":20,"type":21},750,"ESTIMATED","OBSERVATIONAL","The study is designed to evaluate the short-term and long-term clinical performance and safety of the Symphony and Prodigy thrombectomy systems used in endovascular procedures across the peripheral or pulmonary vasculature.",[25,26,27],"Arterial Thromboembolism","Venous Thromboembolism","Pulmonary Embolism",[27,29,30,31,32,33,34],"Thrombus","Thromboembolism","Aspiration","Aspiration thrombectomy","Anticoagulation","Peripheral vasculature","RECRUITING","2026-06-23",{"date":38,"type":39},"2026-06-26","ACTUAL",{"date":41,"type":39},"2026-02-13",{"date":43,"type":21},"2030-09",{"name":45,"class":46},"Imperative Care, Inc.","INDUSTRY",4,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":71},"100589152","development-and-application-of-a-thrombosis-risk-prediction-model-in-lung-cancer-patients-treated-with-immune-checkpoint-inhibitors-100589152","NCT06950697","Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors","Inclusion Criteria:\n\n* Age ≥18 years\n* Histopathologically confirmed lung cancer diagnosis at enrollment\n* Received at least one dose of a China-approved lung cancer immune checkpoint inhibitor\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Presence of two or more primary cancers\n* Missing data for key variables\n* Inability to comply with follow-up requirements\n* Presence of VTE\u002FATE at the time of ICI initiation",{"count":55,"type":21},2400,"30 Months","The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint inhibitors (ICIs) therapy. The primary questions it aims to address are:\n\n1. What is the real-world incidence of VTE\u002FATE in lung cancer patients receiving immune checkpoint inhibitors?\n2. What are the risk factors and biomarkers for VTE\u002FATE in lung cancer patients receiving immune checkpoint inhibitors?\n3. What is the impact of VTE\u002FATE on the prognosis of lung cancer patients receiving immune checkpoint inhibitors?\n\nResearchers will compare the characteristics and biomarkers of patients with and without ICI-associated VTE\u002FATE to identify novel specific biomarkers for thrombotic events. Furthermore, they will construct a risk assessment model for thrombotic events to provide guidance for precision prevention and treatment in clinical practice.",[59,26,25,60],"Lung Cancer","Immune Checkpoint Inhibitors (ICIs)","2026-04-26",{"date":63,"type":39},"2026-04-30",{"date":65,"type":39},"2019-01-01",{"date":67,"type":21},"2027-12-01",{"name":69,"class":70},"Beijing Chao Yang Hospital","OTHER",5,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100438662","impact-of-covid-19-vaccines-on-cerebrovascular-health-100438662","NCT04992195","Impact of COVID-19 Vaccines on Cerebrovascular Health","Impact of COVID-19 Vaccines on Cerebrovascular Health - a Population-based Study","Inclusion Criteria:\n\nAll consecutive citizens in the CUHK Brain Health Longitudinal Study cohort who received baseline MRI brain.\n\nExclusion Criteria:\n\n1. Citizens with clinically evident stroke or dementia prior to recruitment; or\n2. Citizens who are unable to provide an informed consent; or\n3. Citizen with contraindications to MRI brain, e.g., non-MRI compatible implants, claustrophobia, etc; or\n4. Citizens who had no baseline MRI brain assessment.",true,{"count":81,"type":21},500,"Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may reduce the transmission of and achieve population immunity against the COVID-19 pandemic, which accounted for more than 3.75million deaths worldwide. With World Health Organization's (WHO) effort on ensuring equitable access to COVID-19 vaccines, vaccination rate may increase in the near future.\n\nOn the other hand, vaccination hesitancy has emerged as a major hindrance on the global vaccination campaigns in certain areas due to safety concerns, social factors, and public health policies. For instance, a recent survey conducted in Hong Kong showed a low vaccine acceptance rate of 37%. Long-term safety concerns and post-vaccination events relayed by the social media maybe reasons for vaccination hesitancy. Among which, cerebrovascular accidents (CVA) after vaccination were one of the most frequently reported post-vaccination events. These reports ranged from ischemic strokes in elderly patients with multiple cardiovascular co-morbidities, to hemorrhage strokes in otherwise \"young-and-fit\" adults. While many of these events were investigated by the COVID-19 immunization expert committee, an important premise to address the apprehension of CVA after vaccination is the provision of evidence-based information of the impact of COVID-19 vaccines on brain health.\n\nIn this prospective, longitudinal, observational study, we aim to elucidate the relationship between COVID-19 vaccines and cerebrovascular health in healthy citizens in a population-based cohort.",[84,85,86,87,88,89,90,91,25,26],"Stroke","Stroke, Acute","Stroke, Ischemic","Dementia","Brain Ischemia","Alzheimer Disease","Brain Diseases","Major Adverse Cardiovascular Event","2026-02-21",{"date":94,"type":39},"2026-02-24",{"date":96,"type":39},"2021-07-05",{"date":98,"type":21},"2026-12-31",{"name":100,"class":70},"Chinese University of Hong Kong",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":101},"100468304","doac-in-chinese-patients-with-atrial-fibrillation-100468304","NCT05378035","DOAC in Chinese Patients With Atrial Fibrillation","Direct Oral Anticoagulant Levels in Chinese Patients With Atrial Fibrillation - A Real- World Pharmacokinetic Study","DOAC-REAL","Inclusion Criteria:\n\n* Chinese nonvalvular atrial fibrillation (NVAF) patients on apixaban, dabigatran, edoxaban, or rivaroxaban for 6 months or more.\n* Patients aged 18-80 years old.\n* Patients who are able to provide an informed consent.\n* Patients who are indicated for elective medical procedures that require interruption of direct oral anticoagulants (DOAC) for 48 hours.\n\nExclusion Criteria:\n\n* Patients who developed thromboembolism (e.g. ischemic stroke, ischemic bowel, etc.) or major systemic bleeding (e.g. intracerebral haemorrhage, gastrointestinal bleeding) during DOAC usage.\n* Patients with creatinine clearance by Cockroft-Gault formula ≤ 30 mL\u002Fmin.\n* Patients with inappropriate DOAC dosages with respect to age, body weight, and creatinine clearance.\n* Patients who receive DOAC with indications other than NVAF, such as history of mitral stenosis, metallic heart valve, thrombophilia, venous thromboembolism, etc.\n* Patients with conditions that alter haemostasis besides DOAC use, such as essential thrombocytosis, hepatic congestion, hepatic failure with coagulopathy, etc.","80 Years",{"count":112,"type":21},427,"Direct oral anticoagulants (DOACs) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF). All four DOACs - apixaban, dabigatran, edoxaban, and rivaroxaban - were shown to reduce the risk of major bleeding compared to warfarin. The predictable pharmacokinetic profiles of DOACs also favour their use over warfarin. Together with increasing AF incidence due to population ageing, increased AF detection, and territory-wide reimbursement schemes, DOAC prescriptions have been surging worldwide. In Hong Kong, more than 78,354 patients received DOAC from January 2009 through April 2021 according to the Hospital Authority registry.\n\nThe more liberal use of DOACs has led to new issues that require a thorough understanding of ethnic-specific DOAC pharmacokinetic profiles. For instance, 12- 15% of anticoagulated patients annually required interventional procedures that involve temporary discontinuation of DOAC for 48 hours or more. Although guideline-based periprocedural DOAC interruption resulted in a low 30-day thromboembolism rate of 0.16% - 0.6% in a Caucasian cohort, same measures for elective colonoscopies in a local population-based study resulted in a 30-day periprocedural thromboembolism rate of up to 2.2%. Although these studies cannot be compared directly, the remarkable interethnic discrepancy between the two cohorts warrants further pharmacokinetic and pharmacogenomic studies. More importantly, quantifying residual DOAC levels during the interruption periods may imply on duration of periprocedural DOAC interruption, length of hospital-stay, and the risk of thromboembolic and bleeding complications.\n\nMapping inter- and intra-individual variations in DOAC levels may also impact on the management of ischemic stroke among DOAC recipients. Epidemiological studies have shown alarmingly up to 13% of acute ischemic stroke patients were on anticoagulation prior to stroke onset with increasing number of DOAC. These patients received low rates of recanalization therapy due to apprehension of bleeding complications, thus compromised survival and neurological recovery. A prospective study that reveals Asian-specific DOAC pharmacokinetic profiles may inform cross-disciplinary, territory-wide periprocedural care and acute stroke intervention strategy for the rapidly expanding DOAC population.",[115,84,85,90,91,25,26],"Atrial Fibrillation","2025-01-27",{"date":118,"type":39},"2025-01-29",{"date":120,"type":39},"2022-09-28",{"date":122,"type":21},"2027-12-31",{"name":100,"class":70},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":79,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":130,"targetDuration":132,"studyType":22,"phases":4,"briefSummary":133,"conditions":134,"keywords":149,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":71},"100572008","longitudinal-cohort-of-thrombosis-and-hemostasis-diseases-100572008","NCT06727669","Longitudinal Cohort of Thrombosis and Hemostasis Diseases","Inclusion Criteria:\n\n* Patients who were diagnosed as thrombosis and hemostasis diseases.\n\nExclusion Criteria:\n\n* Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease.\n* Patients with alcohol and drug addictions or mental illness affect their ability to comply with study requirements.\n* According to the investigator, there are conditions that may endanger the patient's safety or affect his\u002Fher compliance.",{"count":131,"type":21},3000,"5 Years","This is a multicenter, prospective, longitudinal, observational cohort study to investigate thrombosis and hemostasis diseases in Chinese patients. This study will collect basic information, diagnostic and treatment information, as well as medical expense information of patients from medical records.The incidence and risk factors of thrombosis and hemostasis diseases, the treatment methods, prognosis and medical expenses of these patients in China will be analyzed. The study will use questionnaire to measure the exposure of patients, and prospectively follow-up to collect the prognosis information.",[135,136,137,138,139,140,27,141,142,143,144,145,146,25,147,148],"Immune Thrombocytopenia","Thrombotic Thrombocytopenic Purpura","Hemophilia A, Acquired","Disseminated Intravascular Coagulation","Thrombophilia","Deep Vein Thrombosis","Thrombotic Microangiopathies","Coagulation Factor Deficiency","Hemophilia A","Hemophilia B","Hemophilia B, Acquired","Platelet Dysfunction","Bleeding Disorder","Thrombosis",[148,150],"Hemostasis","2024-12-05",{"date":153,"type":39},"2024-12-11",{"date":155,"type":39},"2024-11-01",{"date":157,"type":21},"2030-12-31",{"name":159,"class":70},"Peking University People's Hospital",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":170,"phases":171,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":184},"100468937","a-pmcf-study-to-confirm-the-performance-and-safety-of-the-lemaitre-tuftex-single-lumen-embolectomy-catheter-100468937","NCT05386277","A PMCF Study to Confirm the Performance and Safety of the LeMaitre® TufTex Single Lumen Embolectomy Catheter","A Post Market Clinical Study to Confirm the Performance and Safety of the LeMaitre® TufTex Single Lumen Embolectomy Catheter on Patients Undergoing Surgical Treatment for the Removal of Arterial Emboli and\u002For Thrombi","SLC","Inclusion Criteria:\n\n1. Male and female subject, ≥ 18 years of age at time of enrollment.\n2. Subject who is scheduled to undergo surgical treatment for the removal of arterial or venous emboli and\u002For thrombi, where one of the LeMaitre® Embolectomy Catheter will be used.\n3. Subject signed an Informed Consent for participation.\n4. Subject diagnosed with a embolus\u002Fthrombus.\n5. Subjects for whom thrombolytic therapy had failed or was contraindicated.\n\nExclusion Criteria:\n\n1. Co-morbidity that in the discretion of the investigator might confound the results.\n2. Subjects who are unable to read or write.\n3. Pregnant or lactating women at time of enrollment\n4. Subjects who are immune comprised",{"count":169,"type":21},112,"INTERVENTIONAL",[172],"NA","A post market clinical study to confirm the performance and safety of the LeMaitre® TufTex Single Lumen Embolectomy Catheter on patients undergoing surgical treatment for the removal of arterial emboli and\u002For thrombi",[25],"2024-10-16",{"date":177,"type":39},"2024-10-18",{"date":179,"type":39},"2022-01-11",{"date":181,"type":21},"2027-06",{"name":183,"class":46},"LeMaitre Vascular",3]